MiR-141-3p Relative Expression Level from FFPE Samples as Biomarker of Prostate Adenocarcinoma Carcinogenesis in Yogyakarta, Indonesia

Authors

  • Sari Eka Pratiwi Department of Biology and Pathobiology, Faculty of Medicine, Universitas Tanjungpura, Indonesia
  • Sri Nuryani Wahyuningrum Magelang Unit of Health Research and Development, Ministry of Health, Indonesia
  • Rachmagreta Perdana Putri Department of Histology, Faculty of Medicine, Universitas Ahmad Dahlan, Yogyakarta, Indonesia
  • Danarto Danarto Department of Urology, Sardjito Hospital, Yogyakarta, Indonesia
  • Didik Setyo Heriyanto Department of Anatomy Pathology, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada, Yogyakarta, Indonesia
  • Nur Arfian 6Department of Anatomy, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada, Yogyakarta, Indonesia
  • Sofia Mubarika Haryana Department of Histology and Cell Biology, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada, Yogyakarta, Indonesia
  • Indwiani Astuti Department of Pharmacology, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada, Yogyakarta, Indonesia

DOI:

https://doi.org/10.33086/ijmlst.v4i1.2355

Keywords:

BPH, HGPIN, miR-141, PCA, prostate anomaly markers

Abstract

Globally, prostate cancer (PCA) is the second leading cause of male cancer-associated mortality. Micro-RNAs (miRNAs) are small non-coding RNAs considered promising biomarkers for diagnosis, prognosis, and treatment options. A miR-141 expression is frequently dysregulated and influences the development and progression of PCA. This study aimed to identify miR-141 expression level as a marker to differentiate PCA from another prostate anomaly, especially in Yogyakarta. Formalin-fixed paraffin-embedded (FFPE) tissues for each three groups: benign prostatic hyperplasia/BPH, high-grade prostatic intraepithelial neoplasia/HGPIN, and PCA (n=7/group) were stored in a commercial clinical laboratory in Yogyakarta. The total RNA was extracted from FFPE sections using miRNeasy FFPE kit, followed by the quantification of miR-141-3p expression level by RT-PCR. The result showed that miR-141 relative expression level on PCA was higher than other groups and significantly different (P<0.05, Kruskal Wallis test). The mean of the miR-141 relative expression level of BPH, HGPIN, and PCA were 1.04±0.87, 6.44±7.8, and 7.06±8.83, respectively. The relative expression level of miR-141 can potentially be a prognostic biomarker in PCA and could differentiate aggressiveness in prostate anomaly, especially BPH, HGPIN, and PCA.

Downloads

Download data is not yet available.

References

Li Z, Ma YY, Wang J, Zeng XF, Li R, Kang W, et al. Exosomal microRNA-141 is upregulated in the serum of prostate cancer patients. Onco Targets Ther. 2015;9:139–48.

Song CJ, Chen H, Chen LZ, Ru GM, Guo JJ, Ding QN. The potential of microRNAs as human prostate cancer biomarkers: A meta-analysis of related studies. J Cell Biochem. 2018;119(3):2763–86.

Gonzales JC, Fink LM, Goodman OB, Symanowski JT, Vogelzang NJ, Ward DC. Comparison of circulating MicroRNA 141 to circulating tumor cells, lactate dehydrogenase, and prostate-specific antigen for determining treatment response in patients with metastatic prostate cancer. Clin Genitourin Cancer [Internet]. 2011;9(1):39–45.

Watahiki A, Wang Y, Morris J, Dennis K, O’Dwyer HM, Gleave M, et al. MicroRNAs associated with metastatic prostate cancer. PLoS One. 2011;6(9).

Hessvik NP, Sandvig K, Llorente A. Exosomal miRNAs as biomarkers for prostate cancer. Front Genet. 2013;4(MAR):1–9.

Anwar SL, Haryono SJ, Aryandono T, Haryana SM. Micro-RNA: Biogenesis, Fungsi, dan Perannya dalam Proses Karsinogenesis dan Penatalaksanaan Kanker. Yogyakarta: Gadjah Mada University Press; 2017.

Armstrong DA, Green BB, Seigne JD, Schned AR, Marsit CJ. MicroRNA molecular profiling from matched tumor and bio-fluids in bladder cancer. Mol Cancer [Internet]. 2015;1–9.

Chen ZH, Zhang GL, Li HR, Luo JD, Li ZX, Chen GM, et al. A panel of five circulating microRNAs as potential biomarkers for prostate cancer. Prostate. 2012;72(13):1443–52.

Humphries B, Yang C. The microRNA-200 family: small molecules with novel roles in cancer development, progression and therapy. Oncotarget [Internet]. 2015;6(9):6472–98.

Gao Y, Feng B, Han S, Zhang K, Chen J, Li C, et al. The roles of MicroRNA-141 in human cancers: From diagnosis to treatment. Cell Physiol Biochem. 2016;38(2):427–48.

Cortés M, Sanchez‐Moral L, de Barrios O, Fernández‐Aceñero MJ, Martínez‐Campanario M, Esteve‐Codina A, et al. Tumor‐associated macrophages (TAMs) depend on ZEB1 for their cancer‐promoting roles. EMBO J [Internet]. 2017;36(22):3336–55.

Burk U, Schubert J, Wellner U, Schmalhofer O, Vincan E, Spaderna S, et al. A reciprocal repression between ZEB1 and members of the miR-200 family promotes EMT and invasion in cancer cells. EMBO Rep. 2008;9(6):582–9.

Zhou X, Xia Y, Su J, Zhang G. Down-regulation of miR-141 induced by helicobacter pylori promotes the invasion of gastric cancer by targeting STAT4. Cell Physiol Biochem. 2014;33(4):1003–12.

Agaoglu FY, Kovancilar M, Dizdar Y, Darendeliler E, Holdenrieder S, Dalay N, et al. Investigation of miR-21, miR-141, and miR-221 in blood circulation of patients with prostate cancer. Tumor Biol. 2011;32(3):583–8.

Zhang HL, Qin XJ, Cao DL, Zhu Y, Yao XD, Zhang SL, et al. An elevated serum miR-141 level in patients with bone-metastatic prostate cancer is correlated with more bone lesions. Asian J Androl. 2013;15(2):231–5.

Zhang J, Ma L. MicroRNA control of epithelial–mesenchymal transition and metastasis. Cancer Metastasis Rev. 2012;31:653–62.

Sekhon K, Bucay N, Majid S, Dahiya R, Saini S. MicroRNAs and epithelial-mesenchymal transition in prostate cancer. Oncotarget [Internet]. 2016;7(41):67597–611.

Song C, Chen H, Wang T, Ru G, Ding Q, Yang W. miR-141-3p Suppresses Expression of Androgen Receptors and Functions as a Tumor Suppressor Gene in Prostate Carcinogenesis. Int J Clin Med. 2017;8:55–72.

Cheng HH, Mitchell PS, Kroh EM, Dowell AE, Che L, Siddiqui J, et al. Circulating microRNA Profiling Identifies a Subset of Metastatic Prostate Cancer Patients with Evidence of Cancer-associated Hypoxia. PLoS One. 2013;8(7):e69239.

Mateescu B, Batista L, Cardon M, Gruosso T, De Feraudy Y, Mariani O, et al. MiR-141 and miR-200a act on ovarian tumorigenesis by controlling oxidative stress response. Nat Med. 2011;17(12):1627–35.

Tejero R, Navarro A, Campayo M, Viñolas N, Marrades RM, Cordeiro A, et al. MiR-141 and miR-200c as markers of overall survival in early stage non-small cell lung cancer adenocarcinoma. PLoS One. 2014;9(7):1–9.

Hui L, Bakiri L, Mairhorfer A, Schweifer N, Haslinger C, Kenner L, et al. p38α suppresses normal and cancer cell proliferation by antagonizing the JNK-c-Jun pathway. Nat Genet. 2007;39(6):741–9.

Richardsen E, Andersen S, Melbø-Jørgensen C, Rakaee M, Ness N, Al-Saad S, et al. MicroRNA 141 is associated to outcome and aggressive tumor characteristics in prostate cancer. Sci Rep. 2019;9(1):1–9.

Ali R, El Tabbakh S, El Delgawy W, Kotb A, Desouky MN. microRNA-141 as a diagnostic and prognostic biomarker for prostate cancer in Egyptian population: Pilot study. African J Urol. 2018;24(4):347–52.

Liu C, Liu R, Zhang D, Deng Q, Liu B, Chao HP, et al. MicroRNA-141 suppresses prostate cancer stem cells and metastasis by targeting a cohort of pro-metastasis genes. Nat Commun. 2017;8.

Downloads

Published

2022-04-28

How to Cite

Pratiwi, S. E., Wahyuningrum, S. N. ., Putri, R. P. ., Danarto, D., Heriyanto, D. S. ., Arfian, N., Haryana, S. M. . and Astuti, I. (2022) “MiR-141-3p Relative Expression Level from FFPE Samples as Biomarker of Prostate Adenocarcinoma Carcinogenesis in Yogyakarta, Indonesia”, Indonesian Journal of Medical Laboratory Science and Technology, 4(1), pp. 1–9. doi: 10.33086/ijmlst.v4i1.2355.